

AACR-NCI-EORTC International Virtual Conference
Molecular Targets and Cancer Therapeutics
CME Approved Sessions Worksheet
October 7-10, 2021

Date	Time	Session	Session Title	Approved Credits	Credits Claimed
Thursday, October 7	10:00 a.m. - 11:20 a.m.	Educational Session 1	Exploiting Synthetic Lethality	1.25	
	10:00 a.m. - 11:20 a.m.	Educational Session 2	Novel Clinical Trial Designs and Development of Next-gen Investigators for Complex Anticancer Agents	1.25	
	11:35 a.m. - 12:35 p.m.	Keynote	Welcome and Opening Keynote Address	1.00	
	12:50 p.m. - 2:40 p.m.	Plenary Session 1	Tumor Targeted Conjugates: A Growing Family	1.00	
	2:55 p.m. - 4:30 p.m.	Concurrent Session 1	Clinical Utility and Applications of Computational Technologies	1.50	
		Concurrent Session 2	Drugs Targeting Metabolism	1.50	
		Concurrent Session 3	Extracellular Vesicles as Therapeutic Targets	1.50	
4:45 p.m. - 5:35 p.m.	Keynote	Keynote Address	0.75		
			<i>Maximum Approved Credits for Oct. 7</i>	9.75	TOTAL:
Friday, October 8	10:00 a.m. - 11:50 a.m.	Plenary Session 2	New Drugs on the Horizon	1.25	
	12:05 p.m. - 1:55 p.m.	Plenary Session 3	Bispecific T-Cell Engagers and Next-Gen CAR T Therapies: Pros and Cons of These Strategies	1.00	
	2:10 p.m. - 3:45 p.m.	Concurrent Session 4	Novel Precision Medicine Combination Trials	1.50	
		Concurrent Session 5	Preclinical Models and Predictive Value	1.50	
		Concurrent Session 6	Radiopharmaceuticals Coming of Age	1.50	
			<i>Maximum Approved Credits for Oct. 8</i>	6.75	TOTAL:
	10:00 a.m. - 11:50 a.m.	Plenary Session 4	DNA Damage Response Beyond PARP	1.75	

Saturday, October 9	12:05 p.m. - 1:55 p.m.	Plenary Session 5	Drugging Difficult Targets	1.75	
	2:10 p.m. - 3:45 p.m.	Concurrent Session 7	Targeting Molecular Residual Disease (MRD) with ctDNA Technologies	1.50	
		Concurrent Session 8	Tumor Microbiome	1.50	
		Concurrent Session 9	Protein-Protein Inhibitors (PPI) in Hematologic Malignancies: Challenges and Promise	1.50	
	4:00 p.m. - 5:40 p.m.	Plenary Session 6	New Drugs on the Horizon II	1.75	
			<i>Maximum Approved Credits for Oct. 9</i>	9.75	TOTAL:
Sunday, October 10	10:00 a.m. - 11:50 a.m.	Plenary Session 7	HER2-Directed Therapies - Dedicated to the Memory of José Baselga	1.75	
	12:05 p.m. - 1:55 p.m.	Plenary Session 8	Non T Lymphocyte Immune Effector Cell Therapies	1.75	
	2:10 p.m. - 4:00 p.m.	Plenary Session 9	Protein Degradors and Molecular Glues	1.75	
	4:15 p.m. - 5:45 p.m.	Closing Session	What is the Biggest Roadblock in Anticancer Drug Development in the Next Decade and What Can be done to Mitigate?	1.50	
			<i>Maximum Approved Credits for Oct. 10</i>	6.75	
			<i>Maximum CME Credits Approved</i>	33.00	TOTAL: